Get started
Author

Fabio Ikedo

Observed names: F Ikedo, F. Ikedo, Fábio Ikedo, Ikedo, Fabio, Ikedo, Fábio
Institution: Aché (Brazil)
ORCID: 0000-0002-7313-6350
Observed ORCID: 0000-0002-7313-6350
OpenAlex ID: A5031300189
The effects of prayer, relaxation technique during general anesthesia on recovery outcomes following cardiac surgery
2006 · Fabio Ikedo, Deepak M. Gangahar, et al. · Complementary Therapies in Clinical Practice · 77
Rotavirus Gastroenteritis in Children in 4 Regions in Brazil: A Hospital‐Based Surveillance Study
2009 · Veridiana Munford, Alfredo Elias Gilio, et al. · The Journal of Infectious Diseases · 37
Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures
2018 · Raquel Costa, Bernhard Steinhoff, et al. · Drugs & Aging · 18
PDF
Cross-cultural adaptation and validation of the European Portuguese version of the heartland forgiveness scale
2020 · Fabio Ikedo, Luisa Castro, et al. · Health and Quality of Life Outcomes · 17
PDF
Long‐term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open‐label extension study
2020 · Eugen Trinka, Rodrigo Rocamora, et al. · Epilepsia · 12
PDF
Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6–16 years
2022 · Pierangelo Veggiotti, Sergiusz Józwiak, et al. · Epilepsy & Behavior · 10
PDF
Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal seizures: post hoc analysis of a phase III trial and open-label extension study
2023 · Eugen Trinka, Rodrigo Rocamora, et al. · Therapeutic Advances in Neurological Disorders · 8
PO043 Efficacy of eslicarbazepine acetate versus controlled-release carbamazepine as monotherapy in patients with newly diagnosed partial-onset seizures
2017 · E Ben-Menachem, E Trinka, et al. · Journal of Neurology Neurosurgery & Psychiatry · 6
Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
2022 · Hamada Altalib, Todd Grinnell, et al. · Epilepsia Open · 4
Efficacy of opicapone in different treatment regimens in Parkinson's disease patients with motor fluctuations
2020 · A. Antonini, G. Ebersbach, et al. · Parkinsonism & Related Disorders · 3
Incidence of treatment-emergent adverse events in Parkinson's Disease patients according to baseline body mass index: Post-hoc analysis from double-blind combined BIPARK-I and II data
2019 · R. Costa, J. Ferreira, et al. · Journal of the Neurological Sciences · 2
PDF
Forgiveness, gratitude, loneliness, spiritual well-being and quality of life in palliative care patients
2025 · Fabio Ikedo, Luisa Castro, et al. · Research Square · 1
PDF
Long-term efficacy and safety of eslicarbazepine acetate (ESL) monotherapy: results from BIA-2093-311/EXT study –the 2-year open-label extension of the ESL study (BIA-2093-311) (4165)
2020 · Eugen Trinka, Ana Pereira, et al. · Neurology · 1
Influence of baseline off-time in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II
2019 · A. Santos, J. Ferreira, et al. · Journal of the Neurological Sciences · 1
Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II
2019 · A. Santos, J. Ferreira, et al. · Journal of the Neurological Sciences · 1
PDF
Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson's disease patients: Post-hoc analysis from combined BIPARK-I and II
2019 · A. Santos, A. Lees, et al. · Journal of the Neurological Sciences · 1
PDF
Analysis of Sodium Levels and Hyponatremia Events in Trials of Eslicarbazepine Acetate (ESL) in Pediatric Patients (Aged 4–17 years) (P5.268)
2018 · Inna Vaisleib, Michael Duchowny, et al. · Neurology · 1
Switching entacapone or placebo to opicapone Open-label: Efficacy results of the BIPARK-I 1-year extension study
2017 · J. Ferreira, A. Lees, et al. · Journal of the Neurological Sciences · 1
Effects of minerals and xylitol solution on human nasal epithelium: Water channels upregulation and potential anti-inflammatory properties
2026 · Michelle Sabrina da Silva, Ana Laura Gaspar, et al. · Brazilian Journal of Otorhinolaryngology
Safety and tolerability of adjunctive eslicarbazepine acetate in adolescents with focal-onset seizures: Data from three double-blind, placebo-controlled randomized clinical studies
2021 · Juan-José García-Peñas, Fábio Ikedo, et al. · Journal of the Neurological Sciences
Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal-onset seizures: Post-hoc analysis from a phase III, randomized, double-blind study and a 2-year open-label extension ESL study (4565)
2021 · Eugen Trinka, Rodrigo Rocamora, et al. · Neurology
OFF/-ON-time changes after switching from entacapone or placebo to opicapone in patients ending the BIPARK-I extension study on opicapone 50-mg
2020 · W. Poewe, J.J. Ferreira, et al. · Parkinsonism & Related Disorders
Psychiatric Adverse Events According to Psychiatric History and Current Status: A Post-hoc Analysis of Three Phase III Trials of Adjunctive Eslicarbazepine Acetate in Adults with Focal Seizures (4140)
2020 · Hamada Altalib, Todd Grinnell, et al. · Neurology
Efficacy and Safety of Eslicarbazepine Acetate as add-on Treatment in Adult Patients with Focal-Onset Seizures by Concomitant Antiepiletic Drug: Data from Four Double-Blind Pivotal Phase III Studies (4067)
2020 · João Chaves, Rui Loureiro, et al. · Neurology
Heartland Forgiveness Scale--European Portuguese Version
2020 · Fabio Ikedo, Luisa Castro, et al. · PsycTESTS Dataset
Works count: 37
Citation count: 201
H-index: 7
I10-index: 6
Year
Topic
Type